Journal article
Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
Abstract
ObjectiveTo evaluate cost-utility of infliximab and adalimumab for the treatment of moderate-to-severe ulcerative colitis (UC) refractory to conventional therapies in Canada.MethodsA Markov model was constructed to evaluate incremental cost-utility ratios (ICUR) of 5 mg/kg and 10 mg/kg infliximab and adalimumab therapies compared to 'usual care' in treating a hypothetical cohort of patients (aged 40 years and weighing 80 kg) over a five-year …
Authors
Xie F; Blackhouse G; Assasi N; Gaebel K; Robertson D; Goeree R
Journal
Cost Effectiveness and Resource Allocation, Vol. 7, No. 1,
Publisher
Springer Nature
Publication Date
2009
DOI
10.1186/1478-7547-7-20
ISSN
1478-7547